Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Customer-Obsessed Growth with Joshua Silver | Ep. 18 | Growthwell with Josh Byrd

Founders who obsess over customer needs unlock significantly higher profit margins while building teams that scale

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Josh Byrd · GrowthwellJosh ByrdJoshua SilverRainforest
Share

Key takeaways

01

Founders who obsess over customer needs unlock significantly higher profit margins while building teams that scale

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Customer-obsessed growth is proving to be the key differentiator for businesses aiming to thrive in competitive markets. A study by Deloitte found that customer-centric companies are 60% more profitable than those that aren't. How do entrepreneurs balance relentless customer focus with scaling businesses and building effective teams? What does it take to maintain this ethos while growing a startup?

Customer-centric companies are 60% more profitable than those that aren't.

In the latest episode of Growthwell, host Josh Byrd sits down with Joshua Silver, the Founder and CEO of Rainforest, to explore the art and science of customer-obsessed growth. From his early days at PatientCo to his latest venture in embedded payments, Joshua shares candid insights into building companies that not only solve problems but also deliver transformative value to customers.

The two discuss…

  • Customer Obsession: Joshua discusses how immersing himself in customer environments helped him design intuitive, impactful solutions, and why understanding your customers is non-negotiable for long-term success.
  • Building Scalable Teams: The importance of hiring exceptional talent early, empowering leadership teams, and creating a culture of transparency and accountability.
  • Balancing Growth and Well-being: Joshua reflects on routines, travel, and the personal strategies that help him stay grounded and driven while managing a high-growth business and family life.

Joshua Silver, a seasoned FinTech entrepreneur and payments expert, founded Rainforest with an aim to help software companies monetize payments with cutting-edge technology and exceptional service. Previously, he co-founded Patientco, a healthcare payments company that successfully exited to Waystar, and led LaunchPath Group, advising over 50 software platforms on payment strategies. A Georgia Tech alum and advocate for the Atlanta tech ecosystem, Joshua is passionate about supporting startups, fostering innovation, and sharing insights on embedded payments and company culture.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

JB
Josh ByrdPrincipal

Experienced strategic marketing leader with a focus on strategic demand generation using data-driven techniques including Account Based Marketing (ABM), Marketing Automation, Online Advertising, Social Media, Print, and Public Relations. I love building strong teams who thrive in creatively mixing diverse marketing tactics, both traditional and modern, to realize significant revenue growth.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

JB
Josh Byrd

Principal

Experienced strategic marketing leader with a focus on strategic demand generation using data-driven techniques including Account Based Marketing (ABM), Marketing Automation, Online Advertising, Social Media, Print, and Public Relations. I love building strong teams who thrive in creatively mixing diverse marketing tactics, both traditional and modern, to realize significant revenue growth.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512